PE20091026A1 - Piperidinas heteroaril-sustituidas - Google Patents

Piperidinas heteroaril-sustituidas

Info

Publication number
PE20091026A1
PE20091026A1 PE2008001960A PE2008001960A PE20091026A1 PE 20091026 A1 PE20091026 A1 PE 20091026A1 PE 2008001960 A PE2008001960 A PE 2008001960A PE 2008001960 A PE2008001960 A PE 2008001960A PE 20091026 A1 PE20091026 A1 PE 20091026A1
Authority
PE
Peru
Prior art keywords
phenyl
oxadiazol
piperidine
trifluoromethyl
substituted
Prior art date
Application number
PE2008001960A
Other languages
English (en)
Inventor
Dirk Heimbach
Susanne Rohrig
Dirk Schneider
Ulrich Rester
Eckhard Bender
Mark Meininghaus
Katja Zimmermann
Dmitry Zubov
Anja Buchmuller
Georges Degenfeld
Christoph Gerdes
Michael Gerisch
Mark Jean Gnoth
Grande Yolanda Cancho
Mario Jeske
Kersten Matthias Gericke
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102007057718A external-priority patent/DE102007057718A1/de
Priority claimed from DE102008010221A external-priority patent/DE102008010221A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20091026A1 publication Critical patent/PE20091026A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINAS HETEROARIL SUSTITUIDAS DE FORMULA (I) DONDE A ES UN COMPUESTO DE FORMULA (i), (ii), (iii), ENTRE OTROS; R1 ES FENILO OPCIONALMENTE SUSTITUIDO CON DIFLUOROMETILO, TRIFLUOROMETILO, TRIFLUOROMETOXI, METILSULFONILO, ENTRE OTROS SUSTITUYENTES; R2 ES H, TRIFLUOROMETILO, AMINOMETILO, ALCOXICARBONILO(C1-C4), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALCOXI(C1-C6), ALQUIL(C1-C6)-AMINO, CICLOALQUILO(C3-C7), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-(CICLOPENTILCARBONIL)-3-(4-ETILFENIL)-5-(3-FENIL-1,2,4-OXADIAZOL-5-IL)PIPERIDINA, CIS-(3,5)-1-(CICLOPENTILCARBONIL)-3-[4-(1-METILETIL)FENIL]-5-(3-FENIL-1,2,4-OXADIAZOL-5-IL)PIPERIDINA, CIS-(3,5)-1-(CICLOPENTILCARBONIL)-3-(3-FENIL-1,2,4-OXADIAZOL-5-IL)-5-[4-(TRIFLUOROMETIL)FENIL]-PIPERIDINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES ACTIVADOS POR PROTEASA PAR-1 ACTUANDO COMO INHIBIDORES DE LA AGREGACION PLAQUETARIA SIENDO UTILES EN EL TRATAMIENTO DE INFARTO DE MIOCARDIO, ANGINA, TROMBOSIS VENOSA PROFUNDA
PE2008001960A 2007-11-30 2008-11-24 Piperidinas heteroaril-sustituidas PE20091026A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007057718A DE102007057718A1 (de) 2007-11-30 2007-11-30 Heteroaryl-substituierte Piperidine
DE102008010221A DE102008010221A1 (de) 2008-02-20 2008-02-20 Heteroaryl-substituierte Piperidine

Publications (1)

Publication Number Publication Date
PE20091026A1 true PE20091026A1 (es) 2009-07-26

Family

ID=40580130

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001960A PE20091026A1 (es) 2007-11-30 2008-11-24 Piperidinas heteroaril-sustituidas

Country Status (20)

Country Link
US (2) US8119663B2 (es)
EP (1) EP2227466B1 (es)
JP (1) JP5450435B2 (es)
KR (1) KR20100114018A (es)
CN (1) CN101932577B (es)
AR (1) AR069417A1 (es)
AT (1) ATE506359T1 (es)
CA (1) CA2706991A1 (es)
CL (1) CL2008003473A1 (es)
DE (1) DE502008003324D1 (es)
DK (1) DK2227466T3 (es)
HK (1) HK1152311A1 (es)
HR (1) HRP20110510T1 (es)
PA (1) PA8805201A1 (es)
PE (1) PE20091026A1 (es)
PL (1) PL2227466T3 (es)
PT (1) PT2227466E (es)
TW (1) TW200936135A (es)
UY (1) UY31484A1 (es)
WO (1) WO2009068214A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022895A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
EP2585441A4 (en) * 2010-06-28 2013-10-09 Hetero Research Foundation PROCESS FOR OLMESARTAN MEDOXOMIL
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
AU2011316550A1 (en) 2010-10-12 2013-05-02 Zafgen, Inc Sulphonamide compounds and methods of making and using same
WO2012054510A1 (en) * 2010-10-19 2012-04-26 Comentis, Inc. Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
MX2015005732A (es) 2012-11-05 2015-12-16 Zafgen Inc Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
CN103965095A (zh) * 2013-02-04 2014-08-06 艾琪康医药科技（上海）有限公司 1-r1-3-r2-4-氟哌啶及其衍生物的制备方法
CN104341590A (zh) * 2013-08-01 2015-02-11 韩冰 一种树枝状高分子化合物及其制备和用途
JP7413346B2 (ja) 2019-03-06 2024-01-15 第一三共株式会社 ピロロピラゾール誘導体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951618B (en) * 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
PT885215E (pt) * 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
WO1997036873A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US6403612B2 (en) * 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
CN1243735C (zh) * 2001-04-19 2006-03-01 卫材株式会社 2－亚氨基吡咯烷衍生物
ATE345799T1 (de) * 2001-10-15 2006-12-15 Janssen Pharmaceutica Nv Substituierte 4-phenyl-4-(1h-imidazol-2-yl)- piperidinderivate zur verringerung von ischämischer schädigung
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP2008504279A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
MXPA06014574A (es) * 2004-06-24 2007-03-12 Incyte Corp Piperidinas n-sustituidas y su uso como farmaceuticos.
WO2006002349A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EA200700251A1 (ru) 2004-08-10 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве фармацевтических средств
DE102004045796A1 (de) * 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
JPWO2006051623A1 (ja) * 2004-11-09 2008-05-29 エーザイ株式会社 トロンビン受容体アンタゴニストを有効成分とするくも膜下出血に伴う血管攣縮の治療剤
CA2621255A1 (en) 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007089683A1 (en) 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
TW200808807A (en) 2006-03-02 2008-02-16 Incyte Corp Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007130898A1 (en) * 2006-05-01 2007-11-15 Incyte Corporation TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1

Also Published As

Publication number Publication date
EP2227466A2 (de) 2010-09-15
PL2227466T3 (pl) 2011-09-30
KR20100114018A (ko) 2010-10-22
CA2706991A1 (en) 2009-06-04
UY31484A1 (es) 2009-07-17
EP2227466B1 (de) 2011-04-20
US20120214788A1 (en) 2012-08-23
ATE506359T1 (de) 2011-05-15
DE502008003324D1 (de) 2011-06-01
JP2011504889A (ja) 2011-02-17
DK2227466T3 (da) 2011-08-08
WO2009068214A2 (de) 2009-06-04
TW200936135A (en) 2009-09-01
JP5450435B2 (ja) 2014-03-26
HRP20110510T1 (hr) 2011-08-31
CN101932577A (zh) 2010-12-29
PT2227466E (pt) 2011-07-01
CN101932577B (zh) 2013-07-17
CL2008003473A1 (es) 2009-08-14
WO2009068214A3 (de) 2009-08-20
AR069417A1 (es) 2010-01-20
US20090306139A1 (en) 2009-12-10
PA8805201A1 (es) 2010-02-12
US8119663B2 (en) 2012-02-21
HK1152311A1 (en) 2012-02-24

Similar Documents

Publication Publication Date Title
PE20091026A1 (es) Piperidinas heteroaril-sustituidas
PE20142099A1 (es) Derivados de sulfonamida
PE20110136A1 (es) Compuestos organicos
PE20191757A1 (es) Compuestos heterociclicos utiles como inhibidores dobles de atx/ca
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20160843A1 (es) Pirrolidinonas herbicidas
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
PE20141421A1 (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20131377A1 (es) Triazina-oxadiazoles
PE20140913A1 (es) Inhibidores de nampt y rock
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20121045A1 (es) Agonista de gpr119
PE20090974A1 (es) Mezclas fungicidas
PE20120430A1 (es) Dicianopiridinas alquilamino-sustituidas
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20110067A1 (es) Derivados de piperidina como inhibidores de renina
PE20070640A1 (es) Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
PE20110843A1 (es) Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
PE20140934A1 (es) Derivados de pirazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal